GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Asset Turnover

BridgeBio Pharma (BridgeBio Pharma) Asset Turnover : 0.30 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BridgeBio Pharma's Revenue for the three months ended in Mar. 2024 was $211.1 Mil. BridgeBio Pharma's Total Assets for the quarter that ended in Mar. 2024 was $697.9 Mil. Therefore, BridgeBio Pharma's Asset Turnover for the quarter that ended in Mar. 2024 was 0.30.

Asset Turnover is linked to ROE % through Du Pont Formula. BridgeBio Pharma's annualized ROE % for the quarter that ended in Mar. 2024 was 11.72%. It is also linked to ROA % through Du Pont Formula. BridgeBio Pharma's annualized ROA % for the quarter that ended in Mar. 2024 was -20.19%.


BridgeBio Pharma Asset Turnover Historical Data

The historical data trend for BridgeBio Pharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Asset Turnover Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial 0.07 0.01 0.08 0.10 0.02

BridgeBio Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.01 - 0.30

Competitive Comparison of BridgeBio Pharma's Asset Turnover

For the Biotechnology subindustry, BridgeBio Pharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BridgeBio Pharma's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Asset Turnover falls into.



BridgeBio Pharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

BridgeBio Pharma's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=9.303/( (623.036+546.38)/ 2 )
=9.303/584.708
=0.02

BridgeBio Pharma's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=211.12/( (546.38+849.333)/ 2 )
=211.12/697.8565
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


BridgeBio Pharma  (NAS:BBIO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

BridgeBio Pharma's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-140.864/-1201.8925
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-140.864 / 844.48)*(844.48 / 697.8565)*(697.8565/ -1201.8925)
=Net Margin %*Asset Turnover*Equity Multiplier
=-16.68 %*1.2101*-0.5806
=ROA %*Equity Multiplier
=-20.19 %*-0.5806
=11.72 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

BridgeBio Pharma's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-140.864/697.8565
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-140.864 / 844.48)*(844.48 / 697.8565)
=Net Margin %*Asset Turnover
=-16.68 %*1.2101
=-20.19 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


BridgeBio Pharma Asset Turnover Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


BridgeBio Pharma (BridgeBio Pharma) Business Description

Traded in Other Exchanges
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Executives
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Frank Mccormick officer: Chairman of Oncology C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Neil Kumar director, officer: See Remarks C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Brian C Stephenson officer: See Remarks 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille director 175 WATER STREET, NEW YORK NY 10038
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Ronald J Daniels director C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee director 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders director 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Andrea Ellis director C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Richard H Scheller director, officer: See Remarks C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990

BridgeBio Pharma (BridgeBio Pharma) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold BridgeBio Pharma Inc Shares

By GuruFocus Research GuruFocus Editor 05-20-2023

BridgeBio Pharma Surges on Positive Heart Drug News

By Stavros Georgiadis, CFA 07-18-2023